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Abstract
Background: Small sample sizes used in previous studies result in a lack of overlap between the reported gene signatures
for prediction of chemotherapy response. Although morphologic features, especially tumor nuclear morphology, are
important for cancer grading, little research has been reported on quantitatively correlating cellular morphology with
chemotherapy response, especially in a large data set. In this study, we have used a large population of patients to identify
molecular and morphologic signatures associated with chemotherapy response in serous ovarian carcinoma.
Methodology/Principal Findings: A gene expression model that predicts response to chemotherapy is developed and
validated using a large-scale data set consisting of 493 samples from The Cancer Genome Atlas (TCGA) and 244 samples
from an Australian report. An identified 227-gene signature achieves an overall predictive accuracy of greater than 85% with
a sensitivity of approximately 95% and specificity of approximately 70%. The gene signature significantly distinguishes
between patients with unfavorable versus favorable prognosis, when applied to either an independent data set (P=0.04) or
an external validation set (P,0.0001). In parallel, we present the production of a tumor nuclear image profile generated
from 253 sample slides by characterizing patients with nuclear features (such as size, elongation, and roundness) in
incremental bins, and we identify a morphologic signature that demonstrates a strong association with chemotherapy
response in serous ovarian carcinoma.
Conclusions: A gene signature discovered on a large data set provides robustness in accurately predicting chemotherapy
response in serous ovarian carcinoma. The combination of the molecular and morphologic signatures yields a new
understanding of potential mechanisms involved in drug resistance.
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Introduction
Ovarian carcinoma (OvCa) remains a leading cause of mortality
from gynecologic cancer, with approximately 21,880 new cases
and 13,850 deaths estimated in the United States in 2010 [1,2].
The standard treatment protocol for advanced-stage epithelial
OvCa is cytoreductive surgery followed by platinum-based
combination chemotherapy. However, the majority of patients
eventually relapse with generally incurable disease, mainly due to
the emergence of chemotherapy resistance [3,4]. Early identifica-
tion and differentiation of patients who are resistant to chemo-
therapy could lead to their enrollment in clinical trials with
alternative therapeutics and is of utmost importance for improving
the outcome of ovarian cancer.
Understanding the molecular mechanisms for chemoresistance
has been the subject of intense research. Various genomic
methodologies [4–12] have been applied to the study of OvCa
to identify a gene signature associated with chemotherapy
response [6,13]. However, there is a lack of overlap between the
discovered genes in different studies [6,14], possibly because of
limited sample size in most studies.
The Cancer Genome Atlas (TCGA), a project of the National
Cancer Institute and the National Human Genome Research
Institute, generates a comprehensive catalog of genomic abnor-
malities with large-scale data sets that include cancers with the
highest mortality rates including serous OvCa. In addition, the
TCGA effort has led to the accumulation of a large set of tumor
images in the repository. It is recognized that cell morphologies are
intimately linked to multiple cell functions, such as cell growth,
apoptosis, differentiation, and migration [15–17]. Switches
between different cell functions can be controlled by regulating
cell shapes [18,19]. It is reported that nuclear size is correlated
with tumor prognosis in Stage III-IV ovarian cancer [20] and is
capable of distinguishing low- from high-grade serous OvCa [21].
However, the molecular mechanism underlying this association
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the opportunity to systematically characterize the morphologic
features associated with chemotherapy response and gene activity.
In this study, we leverage the full scope of the TCGA database
with a large population of patients, including gene expression and
tumor images, to identify the molecular and morphologic
signatures associated with chemotherapeutic response in OvCa.
Integration of the genomic and morphologic dimensions of OvCa
will yield potential insights into mechanism of drug resistance and
facilitate identification of novel system-level events for alternate
therapeutic interventions.
Results
Gene Signature Associated with Chemotherapy
Response in Serous OvCa
To gain insight into the potential mechanisms underlying the
differential response of OvCa to chemotherapy, we perform an
integrated analysis of gene expression and tumor nuclear image
profiles. The 232-sample set that has both gene expression and
image data is used to identify a gene expression pattern that could
predict clinical outcome. The 227 genes most weighted in
achieving the prediction are identified, of which 154 (67.8%)
were downregulated and 73 (32.2%) are upregulated in the
chemoresistant group (Figure 1A; Table S1). The gene expression
fold change cutoff between these two groups is determined on the
basis of the overall predictive accuracy of the patients in this
training set (Figure S1); this cutoff is similar to the one used in the
previous study [9]. The gene expression profiling well separates
the chemoresistant patients from the chemosensitive patients
(Figure 1B) and achieves an overall predictive accuracy of
approximately 87.9% (Figure 1D), with a sensitivity of approxi-
mately 95.2% and specificity of approximately 70% (Figure 1C).
Pathway analysis of the discovered genes reveals an enrichment of
several groups of genes that regulate morphologic changes at the
cellular (approximately 11%), tissue (approximately 13%), and
tumor (approximately 3%) levels (Figure 1E).
Validation of Gene Signature
A validation of the gene signature is performed on an
independent set of 261 samples from TCGA. Based on the score
cutoff from Figure 1D, the predictive model splits the patients into
two groups (Figure 2A) that are well separated from each other
(Figure 2B). 35 patients are identified to have an explicit response
to chemotherapy [22] and 26 of them are correctly predicted
(Figure 2A). Kaplan-Meier analysis of the remaining samples after
removing the patients without survival data shows that the patients
in the low-scoring group exhibited poorer progression-free survival
(PFS) (Figure 2C; median: 22.3 vs 34.2 months; log-rank P=0.04,
HR [95%CI]=0.43 [0.19–0.97]). The clinicopathologic charac-
teristics of patients in these two groups are summarized in Table
S2.
Robustness and scalability of the gene signature are next
evaluated by using the Australian data set which is based on a
different microarray platform. We use it to validate whether the
discovered genes are associated with patient outcome. Overlap
analysis reveals 198 among the 227 genes in this data set (Table
S1). Using the threshold from the reported chemosensitive rates in
ovarian cancer patients (approximately 70% [6]), we group the
,70.0% patients (171 out of 244) with the highest scores into the
high-scoring group and the remaining 30% patients (73 out of 244)
into the low-scoring group (Figure 2D); consistently patients in the
low-scoring group have poorer prognosis (Figure 2E; P,0.0001,
HR [95%CI]=0.36 [0.22–0.56]) where the median PFS of Group
2 (12.0 months) is almost 4 times shorter than that of Group 1
(50.0 months). The clinicopathologic characteristics of the patients
in these two groups either with high scores or with low scores in
both validation sets are detailed in Table S2, which shows the
similar age, tumor stage, and tumor grade distributions as the
TCGA training set (Table 1). Cox proportional hazard analysis
demonstrates that the two groups have significantly different
progression-free survival patterns, independent of age, grade, and
stage (Table S3).
These results not only validate the predictive performance of the
gene signature but also suggest its strong association with tumor
prognosis, which is most likely contributable from chemotherapy
response.
Tumor Nuclear Image Profile Associated with
Chemotherapy Response in Serous OvCa
The results from pathway analysis (Figure 1E) suggests that the
morphologic characteristics may play a key role in determining
chemotherapy response. The tumor nuclear image profile in the
130-sample training set is used to identify a morphologic signature
associated with chemotherapy response; this is then validated using
the 123-sample validation set. The 15 significant features
(FDR#2%, Table S4) consisting of 5 with the highest signal-to-
noise ratios (SNRs) and 10 with the smallest SNRs clearly uncovers
binary patterns in both the training and validation sets, as
illustrated in a similar fashion commonly used in gene expression
profiles (Figure 3A). A detailed version of this panel with
morphological feature names is provided in the Figure S5. More
prominently, we find that the Std_Ar_Bin2 feature (see Methods
and Table S5) values are strongly associated with tumor prognosis.
Based on the Std_Ar_Bin2 feature values, we split the 253 patients
into two groups, where patients with values greater than or equal
to the median are categorized into a group (ie, High Std_Ar_Bin2,
n=129), and patients with values less than the feature median are
categorized a different group (ie, Low Std_Ar_Bin2, n=124)
(Figure 3B). Kaplan-Meier survival analysis demonstrates that
tumors with smaller values of Std_Ar_Bin2 feature have signifi-
cantly poorer overall survival (OS) (Figure 3C, log-rank P=0.001,
HR [95%CI]=1.99 [1.32–3.01]) and poorer PFS (Figure 3D, log-
rank P=0.017, HR [95%CI]=2.72 [1.20–6.19]). Cox propor-
tional hazard analysis demonstrates that the two subgroups, split
on the basis of Std_Ar_Bin2 feature values, have significantly
different OS and PFS patterns, after controlling for age, stage, and
grade (Table S6). These results suggest that morphologic features
are significantly related to patient survival and could serve as
valuable prognostic markers [23].
Integrated Analysis of Morphologic Features and Gene
Signature
Both genomic and morphologic features are associated with
chemotherapy, suggesting that these two types of signatures are
strongly associated with each other. With the patients split into the
two groups based on the Std_Ar_Bin2 feature values, as described
above, we carry out a supervised analysis of the gene expression
data and find that five of the signature genes are significantly lower
(P,0.01) in the Low Std_Ar_Bin2 group (Figure 4A). Similar
analysis is performed on the other morphologic features, and the
corresponding differentially expressed genes are summarized in
Table S7. Next we perform correlation analysis of morphologic
feature data and gene expression data, and the highly correlated
(either positively or negatively) feature-gene pairs (P,0.005) are
depicted in Figure 4B, in which we can see that the morphologic
features are strongly related to the gene signature.
Chemotherapy Response in Serous Ovarian Carcinoma
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36383Figure 1. Gene signature associated with chemotherapy response in serous OvCa. (A) Identification of gene signature differentially
expressed in chemoresistant and chemosensitive patients. (B) The selective genes (n=227) distinguish the chemoresistant patients from the
chemosensitive patients. (C) A predictive model on the basis of the gene signature reveals an accuracy of approximately 87.9% in correctly classifying
chemoresistant and chemosensitive tumors (n=232; green square=chemosensitive, blue triangle=chemoresistant). (D) An receiver operating
characteristic (ROC) curve illustrates the predictive performance, with a sensitivity of approximately 95.2% and specificity of approximately 70% at the
predictive score cutoff of approximately 20.16 that serves as a threshold for patient stratification in the TCGA data set. AUC: area under curve. (E)
Pathway analysis shows that the gene signature is enriched in the morphologic function at cellular, tissue, and tumor levels. The dotted line denotes
the cutoff for significance (P=0.05). The shaded bars show the ratio of genes enriched in each function to the 227 genes.
doi:10.1371/journal.pone.0036383.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36383Figure 2. Validation of gene signature. (A) The predictive model constructed from the TCGA training set was applied to an independent TCGA
validation set (n=261) and split the patients into two groups based on the score cutoff of 20.16 as determined by the ROC curve. Thirty five patients
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Several studies have described chemotherapy response in
ovarian cancer using gene expression profiles, as summarized by
Helleman et al [14]. However, the number of ovarian cancer
specimens used for the gene selection in those studies was relatively
small, ranging from 6 to 119, and the corresponding gene sets
discovered to be associated with platinum-based chemotherapy
resistance exhibited a wide range of 14 to 1,727 genes where only
seven genes were observed as an overlap and each between only
two gene sets [14]. Lack of overlap between the discovered gene
sets is likely due to the limited sample size in most studies.
However, ours is the first study performed on such a large scale,
two genes in the 227-gene set, EPH receptor B3 (EPHB3) and
nuclear factor I/B (NFIB), had been identified in one of the
previous studies [12], and one gene, RNA binding protein 1
(RNABP1), had been identified in a different study [24]. More
prominently, a gene set discovered on a large data set undoubtedly
has high statistical power and robustness in accurately predicting
chemotherapy response. Recently, the TCGA research network
identified 193 prognostic gene signatures predictive of OS, but the
gene association with chemotherapy response remains unexplored
[22]. Here we used a large sample set (493 samples from TCGA
and 244 samples from an external source) for identification of
are identified to have an explicit response to chemotherapy [22]. (B) The two groups are well separated, with 212 patients in the low-scoring group
and 49 in the high-scoring group. (C) Exclusion of patients with no survival data resulted in 109 patients in the low-scoring group and 29 in the high-
scoring group. Kaplan-Meier analysis shows patients in the high-scoring group had poorer progression-free survival (P=0.04). (D) The predictive
model as applied to the external data set distinguishes the patients in the low-scoring group from in the high-scoring group; where the low-scoring
group consists of the 70.1% patients (171 out of 244) with the highest predictive scores, and the high-scoring group consists of the 29.9% patients
(73 out of 244) with the lowest predictive scores (see text for details). (E) Kaplan-Meier analysis shows patients in the high-scoring group had poorer
progression-free survival than those in the low-scoring group (P,0.0001).
doi:10.1371/journal.pone.0036383.g002
Table 1. Clinicopathologic characteristics of TCGA patients with serous OvCa that are used for tumor nuclear image profile and
gene expression profile analyses.
TCGA Cohort
Clinical Chemosensitive Clinical Chemoresistant Totals (All)
No. of patients 172 81 253
Age
Mean, yrs [SD] 59.1 [11.4] 61.7 [11.0] 59.9 [11.4]
Range 30.5–87.5 38–84.7 30.5–87.5
FIGO Stage
"
II 13 0 13
III 134 69 203
IV 25 12 37
WHO Grade
2 29 8 37
3 139 72 211
Unknown 41 5
Surgical outcome
j
Optimal (#1c m ) 70 48 118
Suboptimal (.1c m ) 43 19 62
No macroscopic disease 40 9 49
Unknown 19 5 24
Vital status
Alive 80 14 94
Dead 91 67 158
Unknown 10 1
Recurrent disease
f
Yes 144 81 225
No 28 0 28
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; TCGA, The Cancer Genome Atlas; SD, standard deviation; WHO, World Health Organization.
": Cases were staged according to the 1988 FIGO staging system.
j: Surgical outcome was defined as the size of residual disease at the conclusion of the primary surgical procedure. This field was used to define surgical cytoreduction
as optimal or suboptimal. Optimal was defined as no residual disease greater than 1 cm and included the variable categories of no macroscopic disease (i.e. microscopic
residual disease) and 1 to 10 mm. Suboptimal was defined as residual disease greater than 1 cm and included the variable categories of 11 to 20 mm and greater than
20 mm.
f: Local recurrence after the date of initial surgical resection.
doi:10.1371/journal.pone.0036383.t001
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chemotherapy response. The predictive model on the basis of gene
signature revealed an accuracy of 87.9% in correctly classifying
refractory from responsive tumors in the TCGA training set and
stratified patients in both the TCGA validation set and the
Australian data set into groups that demonstrated significant
discrepancy in tumor progression, suggesting the capacity of the
gene signature to serve as a mechanism to stratify patients with
respect to treatment.
The imaging approach stratifies the cells into 10 bins based on
nuclear size and accounts for the heterogeneity of cells in a
tumor population. Our stratification revealed that most signifi-
cant morphologic features differed between the chemosensitive
and chemoresistant groups in the larger nuclei (range, 300 to 500
pixel
2; Table S2). However, nuclei within this size range account
for a very small percentage (approximately 2.0%), and the
majority of the nuclei (approximately 98.0%) do not show a
significant difference in chemotherapy response. This observation
not only is consistent with the Goldie-Coldman hypothesis [25]
that only a small cell population may contribute to differential
response to chemotherapy, but also suggests the difficulty of a
conventional approach of simply correlating the overall morpho-
logic differences with chemotherapy response, owing to the
‘‘dilution’’ effect [26]. Therefore, our imaging approach allows us
to interrogate different cell populations separated on the basis of
nuclear size in a high throughput and automated fashion.
The 15 morphologic features (Table S4) most weighted in
achieving the patient separation are highly instructive. The same
nuclear parameter might exhibit different or even opposite
patterns. The average roundness of nucleus in Bin 8 (Mean_-
Ro_Bin8) is significantly higher in the chemoresistant group
(P=1.5610
24, Figure S2A), on the contrary, the same nuclear
Figure 3. Tumor nuclear image profile associated with chemotherapy response. (A) The tumor nuclear image profile demonstrates a
strong association with chemotherapy response in both the training set (top) and the validation set (bottom). Each row corresponds to a
morphologic feature, with the columns corresponding to data in different samples. Feature values were median centered across the tumor set and
then log transformed. A detailed version of this panel with morphological feature names is provided in the Figure S5. (B) Feature (Std_Ar_Bin2)
distribution across the entire image sample set (n=253) where patients with values greater than or equal to the feature median are categorized into
a group (i.e., High Std_Ar_Bin2, n=129), and patients with values less than the feature median are categorized a different group (i.e., Low
Std_Ar_Bin2, n=124). Smaller values of Std_Ar_Bin2 feature are significantly associated with poorer OS (C) and poorer PFS (D).
doi:10.1371/journal.pone.0036383.g003
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in the chemoresistant patients (P=0.0015, Figure S2B). The
average roundness of the entire nucleus per sample (Mean_-
Ro_Total) shows no significant difference (P=0.56, Figure S2C).
In addition, none of the image features calculated from the entire
nucleus per sample, the way similar to those used in other studies
[20,21,26], show significant difference between the chemoresis-
tant and chemosensitive patients. This discrepancy from the
previous studies [20] likely results from the number of nuclei
used in the feature calculation. We used approximately 4000
nuclei per sample for feature value calculation, almost 80 times
more than the amount used in the other studies [20,21,26].
Taken together, our approach of binning the nucleus size and
then assessing the image feature in each individual bin improves
the image feature resolution and enhances the discriminating
power. Furthermore, our approach of calculating the morpho-
logic features in separate bins (with smaller size variations) is
capable of alleviating the size dependence of some of the
features, such as circularity and roundness [27].
Aside from the potentially practical value, the morphologic
features also provide insights into cancer morphogenesis. The
chemosensitive patients exhibit a smaller value of nuclear
roundness in Bin 8 (Mean_Ro_Bin8), but with a larger variability
(Std_Ro_Bin8) and a larger aspect ratio (Mean_AR_Bin8). Such
morphologic differences likely result from the active response of
the cells to their environment and heightened cellular metabo-
lism, that is contributable from different molecular regulations
(Figure 4B, Table S7). This is further corroborated by pathway
analysis, which revealed the gene enrichment in the morphologic
function at cellular, tissue, and tumor levels (Table 2). The gene
content of this table offers potential insight into the structural
and molecular mechanisms of the chemotherapy response. The
importance of A2M gene expression is of particular interest, in
view of past work suggesting a correlation between decreased
A2M levels with sensitivity to drugs [28]. A2M is an inhibitor of
matrix metalloproteinase activity, which is reported to contribute
to tissue remodeling and morphogenesis [29,30]. PAX6, which is
associated with drug response, is strongly activated by cotylenin
A in retinoblastoma cell lines [31]. Decreased expression of
Figure 4. Integrated analysis of morphologic features and gene signature. (A) Supervised analysis of gene expression data on the patients
split by the Std_Ar_Bin2 feature values as described by Figure 3B. (B) Correlation of the highly correlated feature-gene pairs (P,0.005), with negative
correlations in green and positive correlations in red.
doi:10.1371/journal.pone.0036383.g004
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chemoresistance by impairing the apoptotic response to cell
damage [12].
In conclusion, a gene signature discovered on a large data set
provides robustness in accurately predicting chemotherapy
response in serous OvCa. Meanwhile, we propose a novel
Table 2. Morphologically related genes at cellular, tissue, and tumor levels.
Gene Entrez Gene Name
Fold
difference* p-value Location
A2M alpha-2-macroglobulin 0.81 2.6E-02 Extracellular Space
AQP5 aquaporin 5 0.81 1.1E-02 Plasma Membrane
AREG amphiregulin 1.51 3.7E-02 Extracellular Space
AVIL advillin 0.77 6.2E-03 Cytoplasm
CALML3 calmodulin-like 3 1.36 5.0E-03 Cytoplasm
CD38 CD38 molecule 0.71 2.0E-02 Plasma Membrane
CNN2 calponin 2 1.24 1.0E-02 Cytoplasm
CXCR4 chemokine (C-X-C motif) receptor 4 0.80 2.6E-02 Plasma Membrane
DDR1 discoidin domain receptor tyrosine kinase 1 0.81 1.2E-03 Plasma Membrane
DKK1 dickkopf homolog 1 (Xenopus laevis) 1.47 2.9E-02 Extracellular Space
EFNB2 ephrin-B2 0.80 3.8E-02 Plasma Membrane
EPHB3 EPH receptor B3 0.76 1.2E-02 Plasma Membrane
FOXA2 forkhead box A2 0.64 4.0E-03 Nucleus
GAP43 growth associated protein 43 1.33 1.6E-02 Plasma Membrane
GDF6 growth differentiation factor 6 1.32 4.0E-02 Extracellular Space
GFRA1 GDNF family receptor alpha 1 1.31 1.2E-02 Plasma Membrane
HES1 hairy and enhancer of split 1, (Drosophila) 0.80 1.4E-02 Nucleus
SD11B2 hydroxysteroid (11-beta) dehydrogenase 2 0.77 1.8E-03 Cytoplasm
ICAM5 intercellular adhesion molecule 5, telencephalin 1.27 2.4E-02 Plasma Membrane
IGFBP5 insulin-like growth factor binding protein 5 0.75 7.0E-03 Extracellular Space
IGHM immunoglobulin heavy constant mu 0.66 7.2E-03 Plasma Membrane
IGKC immunoglobulin kappa constant 0.56 1.7E-03 Extracellular Space
IL15 interleukin 15 1.31 4.6E-02 Extracellular Space
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), member 2 0.78 1.2E-03 Plasma Membrane
LIPG lipase, endothelial 0.73 7.4E-03 Extracellular Space
MATK megakaryocyte-associated tyrosine kinase 1.27 2.2E-03 Cytoplasm
MDK midkine (neurite growth-promoting factor 2) 0.75 2.4E-03 Extracellular Space
EVI1 MDS1 and EVI1 complex locus 0.77 4.6E-03 Nucleus
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 0.69 4.7E-02 Extracellular Space
NPAS3 neuronal PAS domain protein 3 0.70 1.6E-02 Nucleus
NPY neuropeptide Y 1.64 2.8E-02 Extracellular Space
NRG4 neuregulin 4 0.71 8.5E-03 Extracellular Space
NTF5 neurotrophin 4 1.35 3.7E-02 Extracellular Space
PAX6 paired box 6 0.75 1.8E-02 Nucleus
PCSK6 proprotein convertase subtilisin/kexin type 6 0.81 2.4E-02 Extracellular Space
POU2AF1 POU class 2 associating factor 1 0.63 2.0E-03 Nucleus
POU5F1 POU class 5 homeobox 1 1.24 1.1E-02 Nucleus
RTN4R reticulon 4 receptor 0.78 3.4E-04 Plasma Membrane
S100A4 S100 calcium binding protein A4 0.78 4.6E-02 Cytoplasm
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 0.81 1.5E-02 Plasma Membrane
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 1.29 3.4E-02 Extracellular Space
TRPV6 transient receptor potential cation channel, subfamily V, member 6 0.80 6.4E-03 Plasma Membrane
TSPAN7 tetraspanin 7 0.69 1.0E-02 Plasma Membrane
XBP1 X-box binding protein 1 0.80 9.2E-03 Nucleus
*Fold difference in geometric means of chemoresistant tumors (numerator) compared with chemosensitive tumors (denominator).
doi:10.1371/journal.pone.0036383.t002
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terizing patients with nuclear features (such as size, aspect ratio,
and roundness etc) in incremental bins, and we demonstrate that
the tumor nuclear image profile exhibits a strong association with
chemotherapy response. This imaging approach is capable of
accounting for cell heterogeneity and improving the discriminating
power. The integrated approach herein, using gene expression
profile that predicts chemotherapy response coupled with the
morphologic features to stratify patients to the most appropriate
treatment regimen, represents an important step toward the goal
of personalized cancer treatment by identifying the area where
novel drugs can be developed. Although our observations suggest
that the tumor image profile is capable of defining prognosis and
yielding mechanistic insights into the process of chemoresistance,
one limitation of this study is the lack of validation of the image
analysis due to unavailability of the independent image sets
especially in a large population. This issue should be addressed in
the future in order to determine the ultimate value of this
technique in clinical practice. Besides, the resolution dependence
of the morphologic features in separate bins has not been
systematically investigated yet in this study and deserves attention
in the follow-up studies. Future work also consists of inclusion of
more possible morphologic features and verification of the gene-
feature relation identified in this study.
Materials and Methods
Patients and Tissue Samples
Two hundred fifty three OvCa patients in the TCGA database
with explicit platinum status [22] are obtained for nuclear image
profile generation, among which 172 patients are sensitive to
chemotherapy, and 81 are chemoresistant. Platinum status is
defined as resistant if the patient recurred within six months.
Platinum status is defined as sensitive if the platinum free interval
is six months or greater, there is no evidence of progression or
recurrence, and the follow-up interval is at least six months from
the date of last primary platinum treatment [22]. Compared with
patients who are chemosensitive, the chemoresistant patients
exhibit relatively poorer overall survival (OS; median, 53.9 vs. 33.8
months; p,0.0001) and progression-free survival (PFS; median,
25.8 vs. 9.3 months; p,0.0001; Figure S3). Other characteristics
of these 253 patients are listed in Table 1. The average age at
diagnosis is 61.7 years (range, 38.0 to 84.7 years) for the
chemoresistant group and 59.1 years (range, 30.5 to 87.5 years)
for the chemosensitive group. Up to 84% of the chemosensitive
patients show the symptom of recurrent diseases in contrast to
100% of relapse for the chemoresistant patients. 232 among the
253 samples with expression data serve as the TCGA training set
to identify the gene signature, of which 165 are chemosensitive
and 67 are chemoresistant. An independent data set from TCGA
(n=261) and an external data set from an Australian study [32]
are applied for validation of the gene signature. The gene
expression profile in TCGA dataset was performed on three
different platforms (Affymetrix Exon 1.0, Agilent 244 K Whole
Genome Expression Array and Affymetrix HT-HG-U133A) and a
unified expression data set was created by the TCGA research
working group and is available in the TCGA data portal. The
external expression data was performed on the Affymetrix HG-
U133 plus 2 platform and was downloaded from the Gene
Expression Omnibus (accession GSE 9899 [32]). The training set
is used to discover the gene signature and then to create the
predictive model. To be consistent with patient characteristics in
these two data sets, we exclude patients from the Australian data
set who have either non-serous OvCa or grade 2 disease, resulting
in 244 patients in this validation set. The clinicopathologic
characteristics of patients in these two validation data sets are
summarized in Table S2.
Genomic Data Analysis
Expression data are prescreened to remove genes with trivial
variation across the samples and low median expression levels,
resulting in 14,084 genes in the analysis. The gene signature
identified through a supervised method [33] is used for construct-
ing a predictive model using the weighted voting algorithm
[34,35]. A predictive score is assigned to each sample and is
calculated as
Score~
X N
Vf w0
Vf{
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Vf v0
Vf
       
2
4
3
5
,
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3
5
where Vf~wf| xf{ msensitivezmresistant ðÞ =2
  
, N is the number
of discovered genes, wf is the weighting factor, xf is the expression
value and m represents the expression mean for each class. A
sample with a score greater than a cutoff is assigned to the
chemosensitive group, and a sample with a score less than or equal
to the cutoff is assigned to the chemoresistant group. The
predictive accuracy, based on a cutoff score determined by
receiver operating characteristic (ROC) curve, is assessed. The
gene signature is validated on an independent sample set from
TCGA and an external data set [32]. Pathway and network
analysis is performed using Ingenuity Pathway Analysis (IPA,
version 8.6-3003; Ingenuity Systems, Inc.).
Tumor Nuclear Image Profile Generation and Analysis
Nucleus parametric profile generation. An average of
10 high-resolution tumor images (20 X magnification,
10726648 pixels) per sample at the different views of the tissue
blocks are first selected by a pathologist from hematoxylin- and
eosin-stained ScanScope virtual slides, to account for the spatial
heterogeneity of the tumor tissues. Next, we automatically
identify and measure the nuclei in each image by using a cell-
image analysis software (ImageJ, version 1.42, NIH) [36],
producing a parametric profile for each nucleus. In brief, the
first slice of the tumor image is processed using a Fast-Fourier-
transform (FFT) band pass filter with the default setting before
it is converted to a black-white image (features of interest such
as nuclei are displayed as black and the background as white)
by using a threshold value verified by overlaying the segmented
nuclei with the original RGB image. Nuclei with a size range of
50 to 500 pixel
2 and a circularity of greater than 0.3 are
selected for further analysis. The nucleus profile consists of a set
of numbers that describe the nucleus’s characteristics, including
size, location, and shapes that are automatically measured using
the ImageJ Plugins, which is widely used in research [37,38].
Definition of these nuclear parameters is described in details in
the ImageJ user guide [39]. Typically, approximately 4000
nuclei within the size range from 50 to 500 pixel
2 per sample
are produced which is almost 80 times more than the amount
used in other studies [20,21]. An example detailing this
procedure is shown in Figure S4.
Tumor image profile generation. To generate the tumor
image profile, we first split the nuclei into 10 evenly spaced bins
based on the nuclear size, and then calculate the average value and
standard deviation (SD) of these parameters (e.g, area, perimeter,
circularity, aspect ratio, solidity, and roundness) for each nucleus
in each bin as well as for all the nuclei in an image. In addition, the
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percentage (feature name, percentage) are defined as image
features and calculated accordingly. The compactness is defined
as an image feature to qualify the spatial distribution of nuclei
within the tumor tissue. As a result, the tumor image profile
consists of 153 morphologic features including 66 means, 66 SDs,
10 percentages, 10 counts, and 1 compactness (Table S5).
Definition of these nuclear parameters is described in details in
the ImageJ user guide [39].
Tumor image profile analysis. The 253 TCGA samples
with the calculated image profile (described above) are randomly
divided into a 130-sample training set and a 123-sample validation
set in an approximate 1:1 ratio. The training set consists of 90
chemosensitive patients (69.2%) and 40 chemoresistant patients
(30.8%), while the validation set contains 82 chemosensitive
patients (66.7%) and 41 chemoresistant patients (33.3%). The
distribution of chemosensitive and chemoresistant patients in both
the training and validation sets is selected to reflect clinical
chemosensitive rates of approximately 70% [6]. Similar to the
gene expression analysis as stated above, the identification of the
morphologic features associated with chemotherapy response was
performed using the method described previously [7,34] in the
training set and validated in the validation set: In brief, the signal-
to-noise ratio (SNR) is calculated for each potential feature [7,34],
in which positive or negative SNR value indicates the feature
favorable for either the chemoresistant or the chemosensitive
group. The 153 features are ranked on the basis of their SNR
values. The differentially varied morphologic features are deter-
mined in the training set on the basis of FDR#2% and then
validated in the test set. Feature data exhibit a normal distribution
after median centered and log transformed.
Statistical Analysis
OS and PFS curves are generated by the Kaplan-Meier
method, and the statistical significance of survival differences is
determined with the log-rank test. Survival analysis is performed
and an ROC curve is generated using SPSS (version 17.0; SPSS
Inc.) and GraphPad Prism (version 5.04; GraphPad Software,
Inc.). Normality of feature values is verified via a Jarque-Bera test
[40]. The statistical significance of the morphologic signature is
calculated via an unpaired, two-tailed t-test combined with
Benjamini-Hochberg (BH) multiple testing [41]. The p-value of
the identified pathways is assessed by the Fisher exact test using
Ingenuity Pathway Analysis.
Supporting Information
Figure S1 Overall predictive accuracy of patients in the training
set as a function of the gene expression fold change cutoff. The
arrow indicates the fold-change cutoff used in the study that gives
rise to the highest predictive accuracy.
(PDF)
Figure S2 (A) The average roundness of nuclei in Bin 8
(Mean_Ro_Bin8) is significantly higher in the chemoresistant
group (P=1.5 E-04). (B) The same nuclear parameter in Bin 9
(Mean_Ro_Bin9) shows a significant decrease in the chemoresis-
tant group (P=0.0015). (C) The average roundness of the nucleus
in an entire sample shows no significant difference between groups
(Mean_Ro_Total) (P=0.56).
(PDF)
Figure S3 Overall survival (OS) and progression-free survival
(PFS) curves of the 253 patients used for tissue nuclear image
profile generation, among which 172 patients were sensitive to
chemotherapy and 81 of them were chemoresistant.
(PDF)
Figure S4 Flow chart for nucleus parametric profile generation.
(PDF)
Figure S5 Detailed version of Figure 3A including morphologic
feature names.
(PDF)
Table S1 The 227 genes are differentially expressed between
chemoresistant and chemosensitive patients (P,0.05, as identified
by parametric t-test).
(XLS)
Table S2 Clinicopathologic characteristics of patients in the
TCGA and Australia Validation data sets.
(PDF)
Table S3 Cox proportional hazard analysis of progression-free
survival of OvCa patients in the TCGA and Australian validation
data sets in relation to predictive sub-groups (the group with high
predictive scores versus the group with low predictive scores).
(PDF)
Table S4 The 15 morphologic features are differentially varied
between chemoresistant and chemosensitive patients with serous
OvCa (FDR#2%).
(PDF)
Table S5 Image features defined for tumor nuclear image profile
generation.
(PDF)
Table S6 Cox proportional hazard analysis of overall and
progression-free survival of OvCa patients in relation to the
morphological feature value (Std_Ar_Bin2).
(PDF)
Table S7 Significantly expressed gene signatures associated with
each morphologic feature.
(PDF)
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